Format

Send to

Choose Destination
Tissue Antigens. 2014 Oct;84(4):374-60. doi: 10.1111/tan.12445.

Minor histocompatibility antigens: past, present, and future.

Author information

1
Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.

Abstract

Minor histocompatibility (H) antigens are key molecules driving allo-immune responses in both graft-versus-host-disease (GvHD) and in graft-versus-leukemia (GvL) reactivity in human leukocyte antigen (HLA)-matched hematopoietic stem-cell transplantation (HSCT). Dissection of the dual function of minor H antigens became evident through their different modes of tissue and cell expression, i.e. hematopoietic system-restricted or broad. Broadly expressed minor H antigens can cause both GvHD and GvL effects, while hematopoietic system-restricted minor H antigens are more prone to induce GvL responses. This phenomenon renders the latter group of minor H antigens as curative tools for HSCT-based immunotherapy of hematological malignancies and disorders, in which minor H antigen-specific responses are enhanced in order to eradicate the malignant cells. This article describes the immunogenetics of minor H antigens and methods that have been developed to identify them. Moreover, it summarizes the clinical relevance of minor H antigens in transplantation, with special regards to allogeneic HSCT and solid-organ transplantation.

KEYWORDS:

adoptive immunotherapy; allo-immunity; graft-versus-host disease; graft-versus-leukemia effect; hematopoietic stem-cell transplantation; immunogenetics; minor H antigens; organ transplantation

PMID:
25262921
DOI:
10.1111/tan.12445
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center